Tanabe Pharma Corporation
↗Osaka, Japan
Tanabe Pharma Corporation is a leading Japanese pharmaceutical company with a history dating back to 1678. The company specializes in the research, development, and commercialization of innovative therapies for central nervous system (CNS) disorders, autoimmune and inflammatory diseases, diabetes, kidney diseases, and rare conditions. It is globally recognized for its work in neurology, particularly for the development of Radicava (edaravone) for ALS.
In early 2025, the company underwent a major strategic transformation when its parent company, Mitsubishi Chemical Group, sold the unit to Bain Capital for approximately $3.4 billion. Following this acquisition, the company rebranded as Tanabe Pharma Corporation in December 2025. The company is currently focused on advancing its late-stage pipeline, including treatments for Parkinson's disease and rare inherited disorders, while expanding its digital and AI capabilities through partnerships with Microsoft and Hitachi.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:CNS therapeutics and Immunology
SIZE & FINANCIALS
Employees:5001-10000
Revenue:$2.9B
Founded:1678
Ownership:private
Status:operating
FUNDING
Stage:Acquired
Investors:Bain Capital
STOCK
Market Cap:$3.4B (Acquisition Value)
PIPELINE
Stage:Commercial
Lead Drug Stage:Phase 3 / Filed
Modalities:Small molecule, mAb, ADC, Drug-device combinations
Active Trials:250
Trial Phases:Phase 1: 45 | Phase 2: 32 | Phase 3: 18 | Phase 4: 10
FDA Approvals:5
EMA Approvals:4
CORPORATE STRUCTURE
Parent Company:Bain Capital (via K.K. BCJ-94)
Acquired By:Bain Capital (2025-02-01)
Subsidiaries:Tanabe Pharma America, Inc., NeuroDerm Ltd., Tanabe Pharma Europe, Tianjin Tanabe Seiyaku Co., Ltd.
Key Partnerships:Hitachi (AI for clinical trials), Microsoft (Azure OpenAI for security and R&D), Shionogi (Radicava rights transfer), GV20 Therapeutics (AI-informed ADC discovery)
COMPETITION
Position:Leader
Competitors:Takeda, Astellas, Daiichi Sankyo, Eisai, Pfizer, Biogen
LEADERSHIP
Key Executives:
Akihisa Harada - CEO
Akihiro Tsujimura - President & COO
Board Members:Costa Saroukos (Chairman), Ryousuke Tanabe, Yuji Sugimoto
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Tanabe Pharma Corporation. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.